Sitemap Contact Privacy Statement Imprint

Pharmacogenomics of Breast Cancer

Oncology research aim to individualize cancer treatment which relies on the availability of robust prognostic biomarkers and patient specific drugable targets. A top-down approach, i.e. to test biological hypotheses based on prognostic and therapy predictive signals derived from clinical real-world, followed by functional evidence, seems promising. My research focuses on the pharmacogenomics of breast cancer with particular emphasis on estrogen receptor (ER) signaling, a key to endocrine treatment intervention. This includes i) tamoxifen therapy outcome stratification based on the patients’ metabolic capacity, e.g. due to polymorphic enzymes, and other pharmacokinetic/dynamic determinants and their validation in large patient cohorts ii) genome-wide search of novel endocrine and chemotherapy predictive markers, iii) molecular profiling of breast tumor cell models, iv) mechanisms of ER signaling, and v) translational studies to implement diagnostic markers to clinics.

Major Projects
  • Pharmacogenomics of breast cancer
  • Translational research: endocrine therapy
  • Clinical study analysis/evaluation
  • Estrogen receptor regulation
Dr. Werner Schroth

phone: ++49-711-8101 3754

Selected References
  • Schroth, W, U. Hamann, P. A. Fasching, S. Dauser, S. Winter, M. Eichelbaum, M. Schwab and H. Brauch. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) pp
  • Amaral, S., W. Schroth, S. Kugler, P. Fritz, W. Simon and H. Brauch. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer. Breast Cancer Res Treat 2009; 118: 323-331
  • Schroth, W., M. P. Goetz, U. Hamann, P. A. Fasching, M. Schmidt, S. Winter, P. Fritz, W. Simon, V. J. Suman, M. M. Ames, S. L. Safgren, M. J. Kuffel, H. U. Ulmer, J. Bolander, R. Strick, M. W. Beckmann, H. Koelbl, R. M. Weinshilboum, J. N. Ingle, M. Eichelbaum, M. Schwab and H. Brauch. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-36.
  • Rokavec, M., W. Schroth, S. M. C. Amaral, P. Fritz, L. Antoniadou, D. Glavac, W. Simon, M. Schwab, M. Eichelbaum and H. Brauch. A Polymorphism in the TC21 Promoter Associates with an Unfavorable Tamoxifen Treatment Outcome in Breast Cancer. Cancer Research 2008; 68: 9799-808.
  • Jaremko, M., C. Justenhoven, W. Schroth, B. K. Abraham, P. Fritz, C. Vollmert, T. Illig, W. Simon, M. Schwab and H. Brauch. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 2007; 17: 529-38.
  • Schroth, W., L. Antoniadou, P. Fritz, M. Schwab, T. Muerdter, U. M. Zanger, W. Simon, M. Eichelbaum and H. Brauch. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-93.
  • Jaremko, M., C. Justenhoven, B. K. Abraham, W. Schroth, P. Fritz, S. Brod, C. Vollmert, T. Illig and H. Brauch. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat 2005, 25: 232-8.
Major Networks and Collaborations
  • International Tamoxifen Pharmcogenomics Consortium (ITPC)
  • Marie Curie Initial Training Network (ITN) „FightingDrugFailure: Priorities and Standards in Phamacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy“

Curriculum Vitae Werner Schroth, PhD

Scientist at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart
phone: ++49-711-8101 3754
fax: ++49-711-859295
Education and Professional Career
1987-1994 Study of Biology, J.W.Goethe University, Frankfurt, Germany
1995 Diploma in Biology at J.W.Goethe University, Frankfurt, Germany: population genetics in sea turtles
1996 Environmental Research Award, J.W.Goethe University
1996-1998 Employment DFG project ‘microsatellites paternity analyses’, J.W.Goethe University
1997-2000 Dissertation at J.W.Goethe University, Frankfurt, Germany
1999-2000 Research Fellowship Deutsche Bundesstiftung Umwelt DBU
2000 PhD degree at J.W.Goethe University, Frankfurt, Germany: speciation and environmental monitoring in moon jellyfish
2001-2003 Post-doctoral position, ‘evolution of homeobox genes in lower metazoans’, Prof B. Schierwater, ITZ Hannover, Germany
2000-2003 Consultant & scientist-in-charge ‘autoimmune diagnostics’, Dermatological Institute, Prof P. Kind, Offenbach, Germany
2004 to present Scientist in oncology research ‘pharmacogenomics and molecular profiling of breast cancer’, Institute of Clinical Pharmacology, Prof. H. Brauch, IKP Stuttgart, Germany
Professional Memberships
Affiliate membership: American Association for Cancer Research AACR